



NDA 020986/S-079

SUPPLEMENT APPROVAL

Novo Nordisk, Inc.
Attention: Elizabeth D'Amato
Senior Manager, Regulatory Affairs
800 Scudders Mill Road
Plainsboro, NJ 08536

Dear Ms. D'Amato:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 25, 2014, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NovoLog (insulin aspart injection) 100 units/mL.

We also refer to our approval letter dated March 16, 2017, which contained the following error: In the highlights section, under the heading Warnings and Precautions, the last bullet states that HUMALOG U-100 should be administered. HUMALOG U-100 has been replaced with NOVOLOG.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain March 16, 2017, the date of the original approval letter.

This "Changes Being Effected" supplemental new drug application provides for changes to section 5.7, Antibody Production, under Warnings and Precautions in the prescribing information (PI) and for removal of "rDNA origin" from the non-proprietary name on all pieces of labeling, to comply with current labeling guidelines and regulations.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information, text for the patient package insert, instructions for use), with the addition of any labeling changes in

pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 020986/S-079.**” Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Callie Cappel-Lynch, Regulatory Project Manager, at (301) 796-8436.

Sincerely,

{See appended electronic signature page}

Jean-Marc Guettier, M.D.
Director
Division of Metabolism and Endocrinology
Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:

Prescribing Information
Patient Package Insert
FlexTouch Instructions for Use
FlexPen Instructions for Use (previously approved April 17, 2015)
PenFill Instructions for Use
Vial Instructions for Use
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEAN-MARC P GUETTIER
03/16/2017